Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: The cardiovascular health study

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages 3323-3331

  Jovanovich, Anna ^a   Bùžková, Petra ^b   Chonchol, Michel ^a   Robbins, John ^d   Fink, Howard A ^e   De Boer, Ian H ^c   Kestenbaum, Bryan ^c   Katz, Ronit ^b   Carbone, Laura ^f   Lee, Jennifer ^g   Laughlin, Gail A ^l   Mukamal, Kenneth J ^h   Fried, Linda F ⁱ   Shlipak, Michael G ^j   Ix, Joachim H ^k,l,m  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23;

AGED; ARTICLE; BONE DENSITY; CHRONIC KIDNEY DISEASE; COMMUNITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HIP; HIP FRACTURE; HORMONE BLOOD LEVEL; HUMAN; INCIDENCE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; BONE DENSITY; FEMALE; FIBROBLAST GROWTH FACTORS; HIP FRACTURES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; SPINAL FRACTURES;

EID: 84881503881     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1152     Document Type: Article

References (31)

1. Saito H, Maeda A, Ohtomo S, et al. Circulating FGF-23 is regulated by 1, 25-dihydroxy vitamin D3 and phosphorus in vivo. J Biol Chem. 2005;280:2543-2549.
2. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429-435.
3. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003-4008.
4. Prié D, Ureña Torres P, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int. 2009;75:882-889.
5. Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119:2545-2552.
6. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370-1378.
7. Ix JH, Shlipak MG, Wassel CL, Whooley MA. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant. 2010;25:993-997.
8. Isakova T, Xie H, YangW, et al; Chronic Renal Insufficiency Cohort (CRIC) Study Group Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011;305:2432-2439.
9. Kendrick J, Cheung AK, Kaufman JS, et al; HOST Investigators. Elevated FGF-23 associates with death, cardiovascular events and initiation of chronic dialysis. J Am Soc Nephrol 2011;22:1913-1922.
10. Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the 1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004;145:3087-3094.
11. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 2004;314:409-414.
12. Wang H, Yoshiko Y, Yamamoto R, et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res. 2008;23:939-948.
13. Jan de Beur SM. Tumor-induced osteomalacia. JAMA. 2005;294: 1260-1267.
14. Marsell R, MirzaMA, Mallmin H, et al. Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int. 2009;20:1167-1173.
15. Mirza MA, Karlsson MK, Mellström D, et al. Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J Bone Miner Res. 2011;26:857-864.
16. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263-276.
17. Fried LF, Biggs ML, Shlipak MG, et al. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol. 2007;18:282-286.
18. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348:1656-1663.
19. Robbins J, Hirsch C, Whitmer R, Cauley J, Harris T. The association of bone mineral density and depression in an older population.JAm Geriatr Soc. 2001;49:732-736.
20. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. J Clin Epidemiol. 1992;45:683-692.
21. Robinson-Cohen C, Katz R, Mozaffarian D, et al. Physical activity and rapid decline in kidney functionamongolder adults. Arch Intern Med. 2009;169:2116-2123.
22. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049-2060.
23. Stevens LA, Coresh J, SchmidCH, et al. EstimatingGFRusing serum cystatinCalone and in combination with serum creatinine: a pooled analysis of 3, 418 individuals with CKD. Am J Kidney Dis. 2008; 51:395-406.
24. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R. Updated data on proximal femur bone mineral levels of U.S. adults. Osteoporos Int. 1998;8:468-489.
25. Binkley N, Kiebzak GM, Lewiecki EM, et al. Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. J Bone Miner Res. 2005;20:195-201.
26. Ureña Torres P, Friedlander G, de Vernejoul MC, Silve C, Prié D. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int. 2008;73:102-107.
27. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-592.
28. Smith ER, Cai MM, McMahon LP, Holt SG. Biological variability of plasma intact and c-terminal FGF23 measurements. J Clin Endocrinol Metab. 2012;97:3357-3365.
29. Smith ER, Ford ML, Tomlinson LA, et al. Instability of fibroblast growth factor-23 (FGF-23): implications for clinical studies. Clin Chim Acta. 2011;412:1008-1011.
30. Cooper C, Cole ZA, Holroyd CR, et al; IOF CSA Working Group on Fracture Epidemiology. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int. 2011;22:1277-1288.
31. Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137: 529-541.